^
    Back
    Association details:
    Biomarker:KRAS mutation + STK11 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:CI-1040 (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Br J Cancer
    Title:

    LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

    Excerpt:
    …we report that LKB1/KRAS mutant NSCLC cell lines are sensitive to the MEK inhibitor CI-1040 shown by a dose-dependent reduction in proliferation rate…
    DOI:
    10.1038/sj.bjc.6604886